trending Market Intelligence /marketintelligence/en/news-insights/trending/iqcp4tdscyowrn0i2hnjqg2 content esgSubNav
In This List

Akari Therapeutics CEO steps down

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Akari Therapeutics CEO steps down

Akari Therapeutics PLC said CEO and director David Solomon resigned following an internal investigation that revealed he used the company's credit card for personal use.

Akari said it found Solomon violating the drugmaker's policies after incurring personal charges on the company's corporate credit cards.

Clive Richardson, Akari's COO, will head the company in the interim as it searches for a permanent CEO.

The news comes nearly a year after the drugmaker's previous CEO, Gur Roshwalb, resigned after having been found of violating a company policy.